New registry aims to find best treatments for Limited-Stage esophageal cancer

NCT ID NCT06558786

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is creating a database to track how people with esophageal or gastroesophageal junction cancer that has spread to only a few places (like the liver or lymph nodes) are treated in real-world settings. Researchers will collect information from 50 participants to see which standard treatment approaches lead to better outcomes. The goal is to learn more about what works best, not to test a new drug.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
If successful, this study could help doctors identify which treatment combinations work best for patients with limited spread of esophageal cancer.
What could go wrong
This is an observational registry, not a treatment trial, so it won't directly test a new therapy. Results may take years and might not change practice immediately.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGEAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Memorial Sloan Kettering Cancer Center (All Protocol Activities)

    RECRUITING

    New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.